Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldosterone Receptor Blockade in Diastolic Heart Failure
2006-002605-31Phase 2Completed
- Sponsor
- Georg-August-Universität Göttingen
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and chronic heart failure (CHF) comparing spironolactone with placebo (2 arms). Primary endpoint: Change in maximum exercise capacity. Started Nov 2006; status: completed.
02
Drugs
spironolactone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2006-002605-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002605-31.